EPAS1 and clear cell renal carcinoma: In conclusion, our study confirmed that FKBP10 can be a new target for the treatment of clear cell renal cell carcinoma, and inhibiting the expression of FKBP10 can synergistically enhance the antitumor effect of the HIF2α inhibitor PT2385, which opens up new ideas for the clinical treatment of patients with advanced clear cell renal cell carcinoma.